Sho Moriguchi1, Makiko Yamada1, Harumasa Takano1, Tomohisa Nagashima1, Keisuke Takahata1, Keita Yokokawa1, Takehito Ito1, Tatsuya Ishii1, Yasuyuki Kimura1, Ming-Rong Zhang1, Masaru Mimura1, Tetsuya Suhara1. 1. From the Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan; the Department of Neuropsychiatry, Keio University School of Medicine, Tokyo; Decoding and Controlling Brain Information, Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency, Saitama, Japan; and the Department of Psychiatry, National Center of Neurology and Psychiatry, Tokyo.
Abstract
OBJECTIVE: The norepinephrine transporter has been suggested to play a crucial role in major depressive disorder. However, norepinephrine transporter availability in major depressive disorder and its role with clinical symptoms are not known. The authors tested norepinephrine transporter availability in patients with major depressive disorder with the aim to identify any associations between test results and clinical symptoms. METHOD: The present research was a cross-sectional study in which 19 patients with major depressive disorder and 19 age- and sex-matched healthy comparison subjects underwent positron emission tomography scanning to evaluate the norepinephrine transporter availability measured by the radioligand (S,S)-[18F]FMeNER-D2. Norepinephrine transporter availability in the thalamus and its subregions was quantified in terms of nondisplaceable binding potential (BPND). The authors also analyzed the association between norepinephrine transporter availability and clinical symptoms. RESULTS: Compared with healthy subjects, patients with major depressive disorder showed 29.0% higher BPND values in the thalamus and, in particular, 28.2% higher values in the thalamic subregion anatomically connected to the prefrontal cortex. Elevated norepinephrine transporter availability in the thalamus in patients was positively correlated with attention, as measured by the Trail Making Test, part A. CONCLUSIONS: These findings revealed altered norepinephrine transmission in patients with major depressive disorder, suggesting that this alteration could be related to attention in this patient population.
OBJECTIVE: The norepinephrine transporter has been suggested to play a crucial role in major depressive disorder. However, norepinephrine transporter availability in major depressive disorder and its role with clinical symptoms are not known. The authors tested norepinephrine transporter availability in patients with major depressive disorder with the aim to identify any associations between test results and clinical symptoms. METHOD: The present research was a cross-sectional study in which 19 patients with major depressive disorder and 19 age- and sex-matched healthy comparison subjects underwent positron emission tomography scanning to evaluate the norepinephrine transporter availability measured by the radioligand (S,S)-[18F]FMeNER-D2. Norepinephrine transporter availability in the thalamus and its subregions was quantified in terms of nondisplaceable binding potential (BPND). The authors also analyzed the association between norepinephrine transporter availability and clinical symptoms. RESULTS: Compared with healthy subjects, patients with major depressive disorder showed 29.0% higher BPND values in the thalamus and, in particular, 28.2% higher values in the thalamic subregion anatomically connected to the prefrontal cortex. Elevated norepinephrine transporter availability in the thalamus in patients was positively correlated with attention, as measured by the Trail Making Test, part A. CONCLUSIONS: These findings revealed altered norepinephrine transmission in patients with major depressive disorder, suggesting that this alteration could be related to attention in this patient population.
Authors: Thomas Liebe; Meng Li; Lejla Colic; Matthias H J Munk; Catherine M Sweeney-Reed; Marie Woelfer; Moritz A Kretzschmar; Johann Steiner; Felicia von Düring; Gusalija Behnisch; Björn H Schott; Martin Walter Journal: Neuroimage Clin Date: 2018-09-04 Impact factor: 4.881
Authors: Lakshmi N Yatham; Vesna Sossi; Yu-Shin Ding; Nasim Vafai; Shyam Sundar Arumugham; Taj Dhanoa; Raymond W Lam; David J Bond; Joseph H Puyat Journal: Int J Neuropsychopharmacol Date: 2018-02-01 Impact factor: 5.176